Midodrin
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (RS)- N-[2-(2,5-dimetoksifenil)-2-hidroksietil]glicinamid | |||
| Klinički podaci | |||
| Robne marke | Proamatin | ||
| AHFS/Drugs.com | Monografija | ||
| MedlinePlus | a602023 | ||
| Identifikatori | |||
| CAS broj | 133163-28-7 | ||
| ATC kod | C01CA17 | ||
| PubChem[1][2] | 4195 | ||
| DrugBank | DB00211 | ||
| ChemSpider[3] | 4050 | ||
| UNII | 6YE7PBM15H 
| ||
| KEGG[4] | D08220
| ||
| ChEBI | CHEBI:6933
| ||
| ChEMBL[5] | CHEMBL1076
| ||
| Hemijski podaci | |||
| Formula | C12H18N2O4 | ||
| Mol. masa | 254,282 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Sinonimi | 2-amino-N-[2-(2,5-dimetoksifenil)-2-hidroksi-etil]-acetamid | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Midodrin (Amatin, Proamatin, Gutron) je vazopresor/antihipotenzivni agens. Midodrin je odobren u Sjedinjenim Državama od strane FDA 1996 za lečenje disautonomije i ortostatičke hipotenzije.
Avgusta 2010, FDA je predložila povlačenje ovog proizvoda sa tržišta, je proizvođač Shire plc nije kompletirao mandatorne studije nakon početka prodaje leka.[6][7] September 2010, FDA je odobrila da ostane dostupan dok se ne završe studije čiji cilj je prikupljanje podataka o efikasnosti i bezbednosti leka.[8][9]
Midodrin sadrži stereocentar i sastoji se od dva enantiomera. Ovo je racemat, tj. Smjesa od 1: 1 ( R ) i ( S ) - oblik:[10]
| Enantiomeri midodrina | |
|---|---|
 CAS-Nummer: 133163-25-4 |
 CAS-Nummer: 133267-39-7 |
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ U.S. proposes withdrawal of Shire hypotension drug Arhivirano 2022-01-24 na Wayback Machine-u, Aug 16, 2010.
- ↑ O'Riordan, Michael. „FDA recommends withdrawal of midodrine”. Food and Drug Administration. FDA proposes withdrawal of low blood pressure drug [press release]. August 16, 2010.. TheHeart.org. Pristupljeno 1. 4. 2011..
- ↑ Midodrine (ProAmatine, generic) Proposed Market Withdrawal – Update Arhivirano 2012-03-28 na Wayback Machine-u September 10, 2010.
- ↑ Shire Announces Update on ProAmatime September 27, 2011.
- ↑ Rote Liste Service GmbH (Hrsg.): Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, ISBN 978-3-946057-10-9, S. 196.
- Midodrine at drugs.com